LOXO ONCOLOGY, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of April 24, 2014 by and among Loxo Oncology, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
OFFICE LEASE of Suite 520 to LOXO ONCOLOGY, INC A Delaware corporation 400 Oyster Point Boulevard South San Francisco, CA 94080Office Lease • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • California
LOXO ONCOLOGY, INC. FOUNDER’S RESTRICTED STOCK PURCHASE AGREEMENTFounder’s Restricted Stock Purchase Agreement • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • California
This Agreement is made and entered into as of June 28, 2013 (the “Effective Date”) by and between Loxo Oncology, Inc. (the “Company”), a Delaware corporation, and Joshua H. Bilenker (the “Purchaser”).
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of July 3, 2013 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and Loxo Oncology, Inc., a Delaware corporation, having an address at c/o Aisling Capital, 888 7th Avenue, 30th Floor, New York, New York 10106 (“Loxo”).
Sub-Lease AgreementSub-Lease Agreement • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
This Sub-Lease made this 22nd day of November, 2013, by and between Tyr Energy, Inc., having an office at 7500 College Boulevard, Suite 400, Overland Park, Kansas 66210 (hereinafter referred to as “Sub-Lessor”) and Loxo Oncology, Inc., having an address of 1 Landmark Square, Stamford, Connecticut 06901 (hereinafter referred to as “Sub - Lessee”).
